Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma

NCT07646717 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Intrahepatic Cholangiocarcinoma (Icc)

Interventions

DRUG: hepatic arterial infusion chemotherapy (Irinotecan liposome plus 5-FU/LV) combined with lenvatinib and PD-1 inhibitors

Sponsor

Tianjin Medical University Cancer Institute and Hospital